Free Cash Flow Growth (FCF Growth) is the free cash flow of the current year minus the free cash flow from the previous year, divided by last year’s free cash flow. The FCF Growth of ProQR Therapeutics N.V. (NasdaqGM:PRQR) is 0.526993. Free cash flow (FCF) is the cash produced by the company minus capital expenditure. This cash is what a company uses to meet its financial obligations, such as making payments on debt or to pay out dividends. The Free Cash Flow Score (FCF Score) is a helpful tool in calculating the free cash flow growth with free cash flow stability – this gives investors the overall quality of the free cash flow. The FCF Score of ProQR Therapeutics N.V. (NasdaqGM:PRQR) is 1.140353. Experts say the higher the value, the better, as it means that the free cash flow is high, or the variability of free cash flow is low or both.
For the novice investor, the stock market can sometimes be a scary place. Many investors may be ready to jump into the ring, but they might not have the proper training. Finding a stock market strategy that puts the investor on the winning side is not an easy task. There is a plentiful amount of information regarding the equity market. Knowing what information to focus on can be the key to sustained success. Investors who are able to sift through the noise and stick to a sturdy stock picking plan, may be in a much better position when tough portfolio decisions need to be made. Many investors will instinctually want to jump in to a stock that has taken off running. Sometimes this may work out positively, but it can also lead to significant losses and second guessing. If all the proper research is completed, investors may feel more at ease with their selections going forward. Of course there will be times when the research does not turn into expected profits, but knowing how to let go of those stocks may help the investor in the long run.
Checking in on some valuation rankings, ProQR Therapeutics N.V. (NasdaqGM:PRQR) has a Value Composite score of 89. Developed by James O’Shaughnessy, the VC score uses five valuation ratios. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, and price to sales. The VC is displayed as a number between 1 and 100. In general, a company with a score closer to 0 would be seen as undervalued, and a score closer to 100 would indicate an overvalued company. Adding a sixth ratio, shareholder yield, we can view the Value Composite 2 score which is currently sitting at 93.
Watching some historical volatility numbers on shares of ProQR Therapeutics N.V. (NasdaqGM:PRQR), we can see that the 12 month volatility is presently 95.1534. The 6 month volatility is 131.9492, and the 3 month is spotted at 68.6878. Following volatility data can help measure how much the stock price has fluctuated over the specified time period. Although past volatility action may help project future stock volatility, it may also be vastly different when taking into account other factors that may be driving price action during the measured time period.
The Piotroski F-Score is a scoring system between 1-9 that determines a firm’s financial strength. The score helps determine if a company’s stock is valuable or not. The Piotroski F-Score of ProQR Therapeutics N.V. (NasdaqGM:PRQR) is 4. A score of nine indicates a high value stock, while a score of one indicates a low value stock. The score is calculated by the return on assets (ROA), Cash flow return on assets (CFROA), change in return of assets, and quality of earnings. It is also calculated by a change in gearing or leverage, liquidity, and change in shares in issue. The score is also determined by change in gross margin and change in asset turnover.
The MF Rank (aka the Magic Formula) is a formula that pinpoints a valuable company trading at a good price. The formula is calculated by looking at companies that have a high earnings yield as well as a high return on invested capital. The MF Rank of ProQR Therapeutics N.V. (NasdaqGM:PRQR) is 16067. A company with a low rank is considered a good company to invest in. The Magic Formula was introduced in a book written by Joel Greenblatt, entitled, “The Little Book that Beats the Market”.
Shifting gears, we can see that ProQR Therapeutics N.V. (NasdaqGM:PRQR) has a Q.i. Value of 72. The Q.i. Value ranks companies using four ratios. These ratios consist of EBITDA Yield, FCF Yield, Liquidity, and Earnings Yield. The purpose of the Q.i. Value is to help identify companies that are the most undervalued. Typically, the lower the value, the more undervalued the company tends to be.
The C-Score is a system developed by James Montier that helps determine whether a company is involved in falsifying their financial statements. The C-Score is calculated by a variety of items, including a growing difference in net income verse cash flow, increasing days outstanding, growing days sales of inventory, increasing assets to sales, declines in depreciation, and high total asset growth. The C-Score of ProQR Therapeutics N.V. (NasdaqGM:PRQR) is -1. The score ranges on a scale of -1 to 6. If the score is -1, then there is not enough information to determine the C-Score. If the number is at zero (0) then there is no evidence of fraudulent book cooking, whereas a number of 6 indicates a high likelihood of fraudulent activity. The C-Score assists investors in assessing the likelihood of a company cheating in the books.
The Current Ratio of ProQR Therapeutics N.V. (NasdaqGM:PRQR) is 11.39. The Current Ratio is used by investors to determine whether a company can pay short term and long term debts. The current ratio looks at all the liquid and non-liquid assets compared to the company’s total current liabilities. A high current ratio indicates that the company might have trouble managing their working capital. A low current ratio (when the current liabilities are higher than the current assets) indicates that the company may have trouble paying their short term obligations.
The Leverage Ratio of ProQR Therapeutics N.V. (NasdaqGM:PRQR) is 0.101164. Leverage ratio is the total debt of a company divided by total assets of the current and past year divided by two. Companies take on debt to finance their day to day operations. The leverage ratio can measure how much of a company’s capital comes from debt. With this ratio, investors can better estimate how well a company will be able to pay their long and short term financial obligations.
Return on Assets
There are many different tools to determine whether a company is profitable or not. One of the most popular ratios is the “Return on Assets” (aka ROA). This score indicates how profitable a company is relative to its total assets. The Return on Assets for ProQR Therapeutics N.V. (NasdaqGM:PRQR) is -0.773282. This number is calculated by dividing net income after tax by the company’s total assets. A company that manages their assets well will have a higher return, while a company that manages their assets poorly will have a lower return.
The Earnings to Price yield of ProQR Therapeutics N.V. NasdaqGM:PRQR is -0.066075. This is calculated by taking the earnings per share and dividing it by the last closing share price. This is one of the most popular methods investors use to evaluate a company’s financial performance. Earnings Yield is calculated by taking the operating income or earnings before interest and taxes (EBIT) and dividing it by the Enterprise Value of the company. The Earnings Yield for ProQR Therapeutics N.V. NasdaqGM:PRQR is -0.076719. Earnings Yield helps investors measure the return on investment for a given company. Similarly, the Earnings Yield Five Year Average is the five year average operating income or EBIT divided by the current enterprise value. The Earnings Yield Five Year average for ProQR Therapeutics N.V. (NasdaqGM:PRQR) is -0.056928.
The stock investing process may seem intimidating to those just starting out. New investors may have a lot to learn, and they may be wondering where to start. Because there are so many different stock picking strategies, it can be hard to find one specific one to latch on to. Keeping things simple might be a good way to approach the market for beginners. The day to day market happenings can get overwhelming not only for amateurs but professional investors as well. Finding that first little advantage can make all the difference when picking stocks. Many new investors may have the tendency to make too many trades at first without doing the proper research. Easing in to the process may give some much needed perspective for attaining long-term success in the stock market.